OrthoPediatrics (NASDAQ:KIDS) Downgraded by Wall Street Zen to Sell

OrthoPediatrics (NASDAQ:KIDS) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also recently commented on the company. Canaccord Genuity Group began coverage on OrthoPediatrics in a report on Wednesday, December 10th. They set a “buy” rating and a $24.00 target price for the company. JMP Securities dropped their price target on OrthoPediatrics from $35.00 to $25.00 and set a “market outperform” rating for the company in a research report on Friday, October 10th. Truist Financial set a $18.00 price objective on OrthoPediatrics in a research note on Friday, October 10th. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a report on Wednesday, October 8th. Finally, Stifel Nicolaus lowered their target price on shares of OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, October 10th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

OrthoPediatrics Stock Performance

KIDS opened at $17.07 on Friday. The firm’s fifty day simple moving average is $17.46 and its two-hundred day simple moving average is $19.44. OrthoPediatrics has a 52-week low of $15.28 and a 52-week high of $27.60. The company has a market cap of $428.12 million, a price-to-earnings ratio of -8.75 and a beta of 1.06. The company has a quick ratio of 3.52, a current ratio of 7.40 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Monday, January 9th. The company reported ($0.15) earnings per share for the quarter. The company had revenue of $25.08 million for the quarter. OrthoPediatrics had a negative return on equity of 6.86% and a negative net margin of 20.06%. Equities analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Institutional Trading of OrthoPediatrics

Large investors have recently added to or reduced their stakes in the stock. Prosight Management LP increased its stake in shares of OrthoPediatrics by 319.2% in the 3rd quarter. Prosight Management LP now owns 308,707 shares of the company’s stock worth $5,720,000 after acquiring an additional 235,060 shares during the last quarter. Millennium Management LLC grew its holdings in shares of OrthoPediatrics by 55.3% in the first quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after purchasing an additional 233,873 shares during the period. Harbor Capital Advisors Inc. grew its holdings in shares of OrthoPediatrics by 116.5% in the second quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock valued at $7,173,000 after purchasing an additional 179,733 shares during the period. Deerfield Management Company L.P. increased its position in OrthoPediatrics by 1,153.4% during the third quarter. Deerfield Management Company L.P. now owns 194,109 shares of the company’s stock worth $3,597,000 after purchasing an additional 178,623 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY raised its stake in OrthoPediatrics by 1,607.0% during the first quarter. Paradigm Capital Management Inc. NY now owns 170,700 shares of the company’s stock worth $4,204,000 after purchasing an additional 160,700 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.